Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (IPSC) executive Gregory Russotti, Chief Technology and Manufacturing Officer, reported an automatic sale of 2,587 shares of common stock on September 14, 2026 at $1.93 per share. The footnote states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units and the sale was not at his discretion.
After the transaction, Russotti holds 509,198 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for this transaction.
Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, sold 1,658 shares of common stock on September 14, 2026 at $1.93 per share. According to the company’s disclosure, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and Carr held 502,907 shares directly afterward.
Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 13,850 shares of common stock withheld on September 11, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. After this tax-withholding disposition, he beneficially holds 3,633,839 common shares directly. No Rule 10b5-1 trading plan is reported.
Century Therapeutics, Inc. (IPSC) received a notice that officer Gregory Russotti intends to sell up to 2,587 shares of common stock under Rule 144, with an indicated aggregate market value of $4,994.20 as of September 14, 2026. The shares arise from restricted stock vesting treated as compensation from the issuer on September 11, 2026. A prior sale of 534 shares of common stock for $1,094.43 during the past three months is also reported, and the planned sale is stated to include an amount necessary to cover a tax obligation from settlement of the vested equity award.
Century Therapeutics, Inc. (IPSC) is the issuer for a planned sale of common stock reported on behalf of officer Douglas Carr under Rule 144. The notice covers up to 1,658 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an estimated aggregate sale price of $3,200.77.
The shares to be sold arise from restricted stock vesting on September 11, 2026, received from the issuer as compensation. In the prior three months, Carr reported additional sales of 275 shares on August 3, 2026 for $543.73 and 254 shares on September 8, 2026 for $520.57. A remark states that the sale includes shares to cover a tax obligation from settlement of a vested equity award distribution.
Century Therapeutics, Inc. (symbol: IPSC) is the issuer of record for a Form 4 filing submitted to the SEC. Truitt Joseph reported acquisition or exercise transactions in this Form 4 filing.
Century Therapeutics, Inc. (IPSC) reported that director Joseph Truitt received a grant of 148,000 stock options on September 9, 2026, each exercisable for one share of common stock at $2.03 per share and expiring on September 9, 2036. The options vest in equal monthly installments over 36 months, subject to his continued service to the company. Following this grant, he holds 148,000 options directly.
Century Therapeutics, Inc. (IPSC) filed an initial statement of beneficial ownership on Form 3 for Joseph Truitt, who is identified as a director of the company. The filing does not list any equity transactions, holdings, or derivative positions for Truitt and includes a remark referencing an Exhibit 24 Power of Attorney.
Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 463 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This tax-withholding disposition was priced at $2.11 per share, and he now directly holds 3,633,839 common shares. No Rule 10b5-1 trading plan is reported for this transaction.
Century Therapeutics, Inc. (IPSC) reported that Chief Technology and Manufacturing Officer Gregory Russotti sold 534 shares of common stock on September 8, 2026 at $2.05 per share. A footnote states these shares were sold automatically to cover tax withholding obligations related to vesting restricted stock units and not at his discretion.
After this transaction, Russotti held 511,785 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for these transactions.
Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, had an automatic sale of 254 shares of common stock on September 8, 2026 at $2.05 per share. According to the footnote, the sale covered tax withholding obligations from vesting restricted stock units, was not discretionary, and left him holding 504,565 shares directly.